anastrozole and Elevated Cholesterol studies

Research Excerpts

Excerpt	Relevance	Reference
"In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole."	9.17	Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013)
"In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole."	5.17	Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013)

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Clinical Fracture Rate: Number of Participants With Bone Fractures.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Goss, PE	1
Ingle, JN	1
Pritchard, KI	1
Ellis, MJ	1
Sledge, GW	1
Budd, GT	1
Rabaglio, M	1
Ansari, RH	1
Johnson, DB	1
Tozer, R	1
D'Souza, DP	1
Chalchal, H	1
Spadafora, S	1
Stearns, V	1
Perez, EA	1
Liedke, PE	1
Lang, I	1
Elliott, C	1
Gelmon, KA	1
Chapman, JA	1
Shepherd, LE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573]	Phase 3	7,576 participants (Actual)	Interventional	2003-06-06	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years

Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence

Intervention	Participants (Count of Participants)
Exemestane	358
Anastrozole	354

Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years

Event-free Survival

Intervention	Participants (Count of Participants)
Exemestane	157
Anastrozole	164

Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years

Overall Survival: Percentage of Participants Alive at 5 Years

Intervention	percentage of participants (Number)
Exemestane	88
Anastrozole	89

Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years